New drug trial hopes to regrow hair in severe alopecia

NCT ID NCT07205159

Recruiting now Disease control Sponsor: Forte Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 24 times

Summary

This early-stage study tests a new medicine called FB102 for people with severe to very severe alopecia areata, a condition causing major hair loss. About 32 adults will receive either FB102 or a placebo to see if the drug is safe and helps hair grow back. The main goal is to check for side effects and measure changes in scalp hair coverage over 16 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Auckland
NOT_YET_RECRUITING

Auckland, Auckland, 0632, New Zealand
Christchurch
NOT_YET_RECRUITING

Christchurch, Canterbury, 8013, New Zealand
Coorparoo
RECRUITING

Coorparoo, Queensland, 4151, Australia
Palmerston North
NOT_YET_RECRUITING

Palmerston North, Palmerston North Central, 4414, New Zealand
South Yarra
NOT_YET_RECRUITING

South Yarra, Victoria, 3141, Australia
St Leonards
NOT_YET_RECRUITING

Saint Leonards, New South Wales (nsw), 2065, Australia

Conditions

Explore the condition pages connected to this study.

ALOPECIA AREATA